Compounders Research Compare

Genprex, Inc.(GNPX)

Biotechnology · Austin, TX

$2.61-0.11 (-4.04%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Genprex, Inc.

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Austin, TX

13 employees

www.genprex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ryan Confer

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T21:07:05.956Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:07:05.956Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,317,880
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 15,154,203
TTM free cash flow · period ending 2026-06-30: -15,562,720

FMP input reference: 325841a12d79c3b22e4488d0564adef7d4bfa7ba78e5cc1d4c3dcb4b1cd6f762

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GNPX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

GNPX Competitors' EV/FCF Ratio

Genprex, Inc.

Current

Market Cap

$1.32M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.33M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Artelo Biosciences, Inc.

Market Cap

$1.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Jupiter Neurosciences, Inc.

Market Cap

$1.39M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INVO Fertility, Inc.

Market Cap

$1.42M

EV/FCF Ratio

N/A

TTM Avg

7.22x

3Y Avg

7.22x

5Y Avg

7.22x

Curis, Inc.

Market Cap

$1.46M

EV/FCF Ratio

N/A

TTM Avg

56.09x

3Y Avg

56.09x

5Y Avg

56.09x

IM Cannabis Corp.

Market Cap

$1.17M

EV/FCF Ratio

N/A

TTM Avg

8.03x

3Y Avg

7.79x

5Y Avg

7.79x

NEXGEL, Inc.

Market Cap

$1.47M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMGC Holdings Inc.

Market Cap

$1.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cellyan Biotechnology Co., Ltd

Market Cap

$1.13M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Genprex, Inc. (GNPX)	$1.32M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.33M	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.34M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.39M	N/A	N/A	N/A	N/A
INVO Fertility, Inc. (IVF)vs ›	$1.42M	N/A	7.22x	7.22x	7.22x
Curis, Inc. (CRIS)vs ›	$1.46M	N/A	56.09x	56.09x	56.09x
IM Cannabis Corp. (IMCC)vs ›	$1.17M	N/A	8.03x	7.79x	7.79x
NEXGEL, Inc. (NXGL)vs ›	$1.47M	N/A	N/A	N/A	N/A
PMGC Holdings Inc. (ELAB)vs ›	$1.49M	N/A	N/A	N/A	N/A
Cellyan Biotechnology Co., Ltd (HKPD)vs ›	$1.13M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics